Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Nurix Therapeutics has announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, a promising oral BTK degrader drug candidate. The deal includes a $700 million upfront payment to Nurix with potential milestones totaling up to $2.3 billion. The partnership aims to advance clinical development in malignant hematolog…